Antibody Drug Conjugate News and Research

RSS

Researchers use novel imaging technique for precise assessment of spinal degeneration

Research by a Barrow Neurological Institute neurosurgery team on novel imaging technique assessment of patients with lumbar spine degeneration was published in the Aug. 28 issue of PLOS ONE.

20 Oct 2017

Researchers identify protein that offers likely target for treating high-risk pediatric cancers

Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

11 Sep 2017

NIH funds BU ADC with $5.4 million grant to advance research on Alzheimer's disease

The National Institutes of Health/National Institute on Aging has awarded the Boston University Alzheimer's Disease Center a three-year, $5.4 million grant to continue research on ways to reduce the human and economic costs of Alzheimer's disease (AD) through the advancement of knowledge.

26 Aug 2017

History of traumatic brain injury not related to cognitive decline, study shows

Although much research has examined traumatic brain injury (TBI) as a possible risk factor for later life dementia from neurodegenerative diseases such as Alzheimer's disease (AD), little is known regarding how TBI influences the rate of age-related cognitive change.

5 Jul 2017

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

New research presented at the American Society of Clinical Oncology 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody-drug conjugate with a common chemotherapy agent has a high complete-response rate in children and young adults with relapsed or refractory Hodgkin lymphoma.

6 Jun 2017

Some types of cancers are heavily dependent on sugar, study shows

In a new study, scientists at The University of Texas at Dallas have found that some types of cancers have more of a sweet tooth than others.

26 May 2017

Antibody drug conjugate could hold promise in improving treatment for childhood ALL

Researchers at The University of Manchester have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia.

From The University of Manchester 19 May 2017

TSRI researchers develop novel drug delivery method for treating cancers

Scientists from the Florida campus of The Scripps Research Institute have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors.

16 Mar 2017

Bruker showcases innovative high-performance systems and high-value analytical solutions at Pittcon 2017

Bruker (NASDAQ: BRKR) is showcasing a selection of innovative high-performance systems and high-value analytical solutions at Pittcon 2017 (www.pittcon.org), with an emphasis on pharma and applied markets, as well as on nano-materials research and microscopy.

From Bruker BioSpin - NMR, EPR and Imaging 7 Mar 2017

TSRI scientists receive $3.3 million NIH grant to create new breast cancer treatments

A pair of scientists from the Florida campus of The Scripps Research Institute have been awarded up to $3.3 million from the National Cancer Institute of the National Institutes of Health to create the next generation of breast cancer treatments for the thousands of patients whose current treatment options are limited.

14 Feb 2017

Aerobic exercise could help wounded warriors recover from mild traumatic brain injury

Improvised explosive devices and associated blast injuries have left over 350,000 U.S. service members in Iraq and Afghanistan with an invisible wound: traumatic brain injury.

25 Jan 2017

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

The combination of two new drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.

6 Dec 2016

Researchers identify new strategy to selectively sensitize cancer cells to radiation therapy

Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects.

5 Oct 2016

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer.

8 Aug 2016

Penn's ADCC receives $8.8 million grant to continue research on treatment for AD and related dementias

The University of Pennsylvania's Alzheimer's Disease Core Center has been awarded an estimated $8.8 million over five years from the National Institute on Aging to continue its mission of investigating mechanisms, diagnostics, treatments and strategies for Alzheimer's Disease (AD) and related dementias including Parkinson's disease (PD), Parkinson's disease dementia (PDD), Lewy Body dementia (LBD) and frontotemporal lobar degeneration (FTLD).

3 Aug 2016

Rapid number naming test can detect cognitively impaired people with AD

For the first time, researchers have determined that a brief, simple number naming test can differentiate between cognitively healthy elderly individuals and cognitively impaired people with Alzheimer's disease (AD), including those with mild cognitive impairment (MCI), as well as those with AD dementia.

6 Jul 2016

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

EORTC study examines DW-MRI in patients with resectable liver metastases from colorectal cancer

Diffusion weighted (DW) magnetic resonance imaging (MRI) is a widely used technique to detect and characterize cancers as well as to monitor response to therapy. DW-MRI offers numerous advantages for patients with cancer and their treating physicians. It is a non-invasive imaging tool which does not require the administration of contrast agents nor ionizing radiation.

5 Jan 2016

Ajinomoto Althea expands biological drug product manufacturing operations

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).

10 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015